Critical Evaluation of Clinical Data on Lyndiol
Kopera, H.; Dukes, M.N.; Ijzerman, G.L.
International Journal of Fertility 9: 69-74
1964
ISSN/ISBN: 0020-725X PMID: 14106270 Document Number: 479555
Data produced by 49 investigators in 13 countries on 2061 women treated with Lyndiol for 9496 cycles were analyzed. In none of the women using the preparation according to instructions (one tablet a day from day 5 to day 24 of the cycle) did pregnancy occur. Withdrawal bleeding followed with great regularity 3 to 5 days after the last tablet and had a mean duration of 3 to 5 days; the blood loss was frequently smaller than in normal menstruation. Side effects were remarkably few. Nausea and vomiting was recorded during the first cycle in less than 14% of the subjects and subsided with a rapid decline in frequency during the next 3 cycles and complete cessation after the 4th cycle. Breakthrough bleeding and spotting were encountered in not more than 1.7% of the cycles, and thus present no problem. About 14% of the women experienced unwanted or wanted effects on the mammae, and in less than 4% was an increase in appetite and body weight recorded. The rest of the incidentally reported side effects were negligible. Composition of Lyndiol: 5 mg of 17-ethinyl-3-desoxo-19-nortes-tosterone and 150 mcg of ethinyl-estradiol-3-methyl ether/tablet.